8-K
filed May 22, 2023, 7:59 PM ET
ticker CBIO
CIK 0001253689
other material
confidence high
sentiment neutral
materiality 0.15
GlycoMimetics stockholders elect all director nominees, ratify auditor, approve say-on-pay
CRESCENT BIOPHARMA, INC.
- Three director nominees elected: Andrews (36.2M for, 0.5M withheld), Goldberg (32.6M/4.0M), Pearson (36.3M/0.4M); 14.2M broker non-votes.
- Ratification of Ernst & Young as auditor approved: 50.3M for, 0.5M against, 0.05M abstained.
- Advisory vote on executive compensation approved: 36.1M for, 0.4M against, 0.1M abstained; 14.2M broker non-votes.
- Approximately 79% of outstanding shares (50.9M of 64.2M) represented at the meeting.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
CRESCENT BIOPHARMA, INC. shareholders approved To approve, on an advisory basis, the executive compensation of the Company's named executive officers as disclosed in the proxy materials. at the 2023-05-19 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-19
Exact text from the filing
Proposal No. 3: To approve, on an advisory basis, the executive compensation of the Company's named executive officers as disclosed in the proxy materials. The votes were cast as follows: Votes For Votes Against Abstained Approved, on an advisory basis, the executive compensation. 36,116,823 435,570 112,283 Broker Non-Votes: 14,198,293.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
CRESCENT BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-19 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-19
Exact text from the filing
Proposal No. 2 : Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Ernst & Young 50,337,103 474,059 51,807
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
CRESCENT BIOPHARMA, INC. shareholders approved Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2023-05-19 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-19
Exact text from the filing
Proposal No. 1 : Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Patricia Andrews 36,190,925 473,751 Mark Goldberg, M.D. 32,642,583 4,022,093 Timothy Pearson 36,279,306 385,370 Broker Non-Votes: 14,198,293. All nominees were elected.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.